Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
PHAT on Nasdaq
Shares outstanding
77,117,778
Price per share
$13.50
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
61,961,758
Total reported value
$1,025,526,440
% of total 13F portfolios
0%
Share change
-479,431
Value change
-$4,011,551
Number of holders
171
Price from insider filings
$13.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Frazier Life Sciences Public Fund, L.P. 8.6% 0% $70,447,299 5,985,327 0% James N. Topper 01 Nov 2025
Carlyle Group Inc. 4.9% $30,142,485 3,496,808 Carlyle Group Inc. 28 Aug 2025
BlackRock, Inc. 4.6% $14,066,607 3,226,286 BlackRock, Inc. 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 2.7% -63% $34,544,824 -$49,760,005 2,082,180 -59% Millennium Management LLC 31 Dec 2025
PRUDENTIAL FINANCIAL INC 0% -100% $8,705 -$24,547,397 2,630 -100% PRUDENTIAL FINANCIAL INC 31 May 2025

As of 31 Dec 2025, 171 institutional investors reported holding 61,961,758 shares of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT). This represents 80% of the company’s total 77,117,778 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 16% 12,466,489 0% 5.6% $206,819,053
Medicxi Ventures Management (Jersey) Ltd 9.7% 7,464,572 0% 15% $123,837,249
Invesco Ltd. 5.1% 3,920,446 +1.4% 0.01% $65,040,200
BlackRock, Inc. 4.6% 3,555,548 +4.5% 0% $58,986,540
Carlyle Group Inc. 4.5% 3,496,808 0% 0.43% $57,977,077
VANGUARD GROUP INC 4.1% 3,177,211 -1.2% 0% $52,709,931
Ensign Peak Advisors, Inc 3% 2,352,020 -6% 0.07% $39,020,012
MILLENNIUM MANAGEMENT LLC 2.7% 2,082,180 -59% 0.02% $34,543,366
NEA Management Company, LLC 2.5% 1,960,169 0% 1.7% $32,519,204
683 Capital Management, LLC 2.3% 1,785,000 -1.9% 2.5% $29,613,150
Catalys Pacific, LLC 1.9% 1,429,014 +22% 7.6% $23,707,342
WASATCH ADVISORS LP 1.7% 1,331,669 -13% 0.13% $22,092,389
GW&K Investment Management, LLC 1.7% 1,306,678 +14% 0.19% $21,678,000
STATE STREET CORP 1.5% 1,149,536 +9.1% 0% $19,070,802
GEODE CAPITAL MANAGEMENT, LLC 1.4% 1,073,434 -1.4% 0% $17,811,321
Propel Bio Management, LLC 0.96% 740,918 +34% 10% $12,291,830
Catalio Capital Management, LP 0.91% 698,996 -38% 2.2% $11,596,344
Divisadero Street Capital Management, LP 0.86% 662,312 0.63% $10,987,756
MOORE CAPITAL MANAGEMENT, LP 0.78% 600,000 0% 0.2% $9,954,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.71% 549,171 +256% 0.01% $9,110,747
SummitTX Capital, L.P. 0.67% 517,820 +34% 0.26% $8,590,634
StepStone Group LP 0.55% 422,085 0% 2.9% $4,967,940
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.52% 397,910 +8.7% 0% $6,601,327
NEXT CENTURY GROWTH INVESTORS LLC 0.51% 393,774 0.45% $6,532,710
GOLDMAN SACHS GROUP INC 0.51% 392,045 +158% 0% $6,504,026

Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 61,961,758 $1,025,526,440 -$4,011,551 $16.59 171
2025 Q3 62,342,014 $733,764,577 +$59,060,358 $11.77 133
2025 Q2 57,415,787 $550,618,405 -$26,654,537 $9.59 117
2025 Q1 64,025,009 $401,391,744 -$24,944,522 $6.27 136
2024 Q4 66,610,653 $540,837,976 -$121,495,122 $8.12 141
2024 Q3 72,636,064 $1,312,668,227 +$264,199,549 $18.08 133
2024 Q2 58,109,780 $598,557,394 +$27,856,700 $10.30 113
2024 Q1 55,378,949 $588,085,973 +$14,631,856 $10.62 112
2023 Q4 54,112,686 $503,299,407 +$11,390,968 $9.13 115
2023 Q3 43,760,270 $452,721,621 +$5,267,236 $10.37 109
2023 Q2 42,778,866 $612,591,768 +$176,400,941 $14.32 103
2023 Q1 30,786,694 $219,689,484 +$28,315,357 $7.14 83
2022 Q4 28,212,747 $316,546,824 -$21,719,929 $11.22 83
2022 Q3 30,185,827 $334,342,526 +$38,042,890 $11.08 87
2022 Q2 27,258,631 $230,064,222 +$9,335,400 $8.44 88
2022 Q1 25,654,888 $349,117,442 -$176,036,740 $13.61 74
2021 Q4 28,574,214 $561,954,045 +$49,942,191 $19.67 82
2021 Q3 25,543,470 $819,833,454 +$19,152,056 $32.10 81
2021 Q2 24,918,954 $843,508,479 +$13,169,188 $33.85 76
2021 Q1 24,475,818 $919,193,673 +$1,760,408 $37.56 82
2020 Q4 24,534,138 $815,024,391 +$96,707,884 $33.22 75
2020 Q3 21,632,831 $793,536,439 -$7,640,662 $36.67 57
2020 Q2 21,847,152 $718,752,879 -$3,025,534 $32.91 59
2020 Q1 21,949,381 $565,607,078 +$3,219,839 $25.82 47
2019 Q4 21,809,755 $677,010,000 +$593,409,007 $31.14 40